Evidence map›Paper›PMID 28417345›Full record

ReviewCurrent treatment options in neurology2017

Imaging Markers for Monitoring Disease Activity in Multiple Sclerosis.

Suradech Suthiphosuwan, David Kim, Aditya Bharatha, Jiwon Oh

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Suradech SuthiphosuwanDivision of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, 30 Bond St. Shuter 3-019, Toronto, ON, M5B1W8, Canada.
David KimDivision of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, 30 Bond St. Shuter 3-019, Toronto, ON, M5B1W8, Canada.
Aditya BharathaDivision of Diagnostic and Therapeutic Neuroradiology, Department of Medical Imaging, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
Jiwon OhDivision of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, 30 Bond St. Shuter 3-019, Toronto, ON, M5B1W8, Canada. ohjiw@smh.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementMultiple sclerosis (MS) is an immune-mediated disease affecting the central nervous system (CNS). Magnetic resonance imaging (MRI) has long been recognized as an important tool in the diagnosis of MS. It is increasingly recognized that in addition to its role in diagnosis, MRI can play a key role as a noninvasive tool for prognostication, disease monitoring, assessment of treatment efficacy, and safety monitoring of disease-modifying therapies (DMTs). A confluence of factors, including increased availability of MRI, development of improved MRI techniques, and increased availability of DMTs have contributed to the expanding role of MRI in MS clinical care. As the clinical use of MRI in MS expands, it is important that MRI protocols amongst clinical centers are standardized. Here, we summarize recent evidence supporting the use of MRI in clinical practice, summarize various clinical guidelines and recommendations for the use of MRI in MS disease monitoring, and provide our recommendations for standardized MRI protocols.

Indexed as

Disease monitoringMRIMultiple sclerosisSafetyStandardized protocolsTreatment efficacy

Identifiers

PMID28417345

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.